Eisai Inc. and Purdue Pharma L.P. have entered into a worldwide collaboration agreement for the development and commercialization of Eisai’s clinical candidate lemborexant (E2006), a dual orexin receptor antagonist entering Phase III clinical development for the treatment of insomnia. Eisai and Purdue Pharma will share the costs of lemborexant global clinical studies. While the potential indication for the product candidate is for the treatment of insomnia, the companies may also seek to deve...